Myeloma CARs are rolling into the clinical arena.
Hudecek M et al. Blood. 2016 Sep 29;128(13):1667-8. doi: 10.1182/blood-2016-08-729467.

Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Bilotti E et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):558-562. doi: 10.1016/j.clml.2016.08.001.

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Kumar SK et al. Blood. 2016 Oct 4. pii: blood-2016-05-717769. [Epub ahead of print].

Beta-blockers Improve Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation.
Hwa YL et al. Am J Hematol. 2016 Oct 12. doi: 10.1002/ajh.24582. [Epub ahead of print].

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
Abedin SM et al. Onco Targets Ther. 2016 Sep 28;9:5943-5953. eCollection 2016.

A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma.
Chari A et al. Br J Haematol. 2016 Oct 7. doi: 10.1111/bjh.14314. [Epub ahead of print].